Clinical Trials Logo

Meningococcal Infections clinical trials

View clinical trials related to Meningococcal Infections.

Filter by:

NCT ID: NCT00311415 Completed - Clinical trials for Prevention of Meningococcal Infection

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children

Start date: October 2005
Phase: Phase 3
Study type: Interventional

Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in healthy children

NCT ID: NCT00310713 Completed - Clinical trials for Prevention of Meningococcal Infection

Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine

Start date: April 2006
Phase: Phase 4
Study type: Interventional

Persistence of antibodies and kinetics of B cell response in healthy children after vaccination with MCC vaccine

NCT ID: NCT00310700 Completed - Clinical trials for Prevention of Meningococcal Infection

Kinetics of B Cell Response in Infants Menjugate Vaccination

Start date: May 2005
Phase: Phase 4
Study type: Interventional

Kinetics of B cell response in infants Menjugate vaccination

NCT ID: NCT00310687 Completed - Clinical trials for Prevention of Meningococcal Infection

Persistence of Immune Response After Vaccination With MCC

Start date: October 2004
Phase: Phase 4
Study type: Interventional

Persistence of Immune response after vaccination with MCC

NCT ID: NCT00310674 Completed - Clinical trials for Prevention of Meningococcal Infection

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age

Start date: September 2004
Phase: Phase 3
Study type: Interventional

Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 months of age

NCT ID: NCT00310635 Completed - Clinical trials for Meningococcal Infection

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

Start date: June 2005
Phase: Phase 4
Study type: Interventional

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

NCT ID: NCT00297817 Completed - Clinical trials for Meningococcal Disease

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

Start date: February 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of two serogroup B meningococcal vaccines in comparison to placebo administered to healthy adolescents ages 11 to 18 years.

NCT ID: NCT00291343 Completed - Clinical trials for Infections, Meningococcal

Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

Start date: February 1, 2006
Phase: Phase 3
Study type: Interventional

This study will be conducted in three stages. In the DTP booster stage at 15 to 24 months of age, all subjects will receive a booster dose of Tritanrix™-HepB/Hiberix™. In the Mencevax™ ACWY "full dose" stage at 24 to 30 months of age all subjects will receive a dose of Mencevax™ ACWY. In the Mencevax™ ACWY "small dose" stage at 30 to 36 months of age, the first 75 subjects in each of the two centers will be tested for boostability of the MenA and MenC immune response by giving a fifth of a dose of a Mencevax™ ACWY vaccine. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00290329 Completed - Clinical trials for Infections, Meningococcal

Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years

Start date: January 14, 2006
Phase: Phase 4
Study type: Interventional

GlaxoSmithKline Philippines has submitted a registration file for its Purified Meningococcal Polysaccharide of Serogroup ACWY Vaccine (Mencevax ACWY). This study is being conducted to collect clinical data in the local target population in order to assess the occurrence of rare adverse events after vaccination as per the requirement of Philippines Bureau of Food and Drugs Directive.

NCT ID: NCT00271479 Completed - Clinical trials for Infections, Meningococcal

Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine

Start date: June 2004
Phase: Phase 4
Study type: Interventional

Hypothesis: Lower doses of each A/C/Y/W135 component of the meningococcal polysaccharide vaccine could confer a similar functional immunogenic response as the dose of 50 μg currently being used, and subsequently be equally protective. The purpose of this study is to evaluate the use of fractional dose tetravalent meningococcal polysaccharide vaccine to control outbreak especially caused by N. meningitidis serogroup W135 Primary Objectives: - To measure the immunogenicity of a dose corresponding to one fifth of the amount of the licensed meningococcal A/C/Y/W135 polysaccharide vaccine, i.e. 10 μg for each component; and - To measure the immunogenicity of a dose corresponding to one tenth of the licensed meningococcal A/C/Y/W135 polysaccharide vaccine, i.e. 5 μg for each component.